ZILRETTA decreased peak systemic exposure
18x lower peak plasma concentration with ZILRETTA
Reduced peak systemic exposure to triamcinolone acetonide (TA) (1144 pg/mL) compared to TAcs (21,062 pg/mL)*
- Results based on a study evaluating concentration of TA in plasma following a single intra-articular injection of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) (n=60) or TAcs (n=18)2
- ZILRETTA: Blood samples were collected periodically over 24 hours and at Weeks 1, 6, 12, 16, and 20
- TAcs: Samples were collected periodically over 24 hours and at Week 6
Based on Cmax levels following a single intra-articular injection of ZILRETTA and TAcs.
TAcs=triamcinolone acetonide crystalline suspension.
ZILRETTA injection demonstrated minimal effect on blood glucose
In a study evaluating a single dose of ZILRETTA (n=18) or TAcs (n=15) in patients with type 2 diabetes, glucose values were 155.2 mg/dL at baseline (average over 72 hours prior to injection) and 163.4 mg/dL post-injection (average over 72 hours post-dosing)1
ZILRETTA demonstrated a statistically significantly smaller least squares mean (LSM) change in average daily blood glucose compared with TAcs (14.66 vs 33.88, P=0.0452).1
The clinical relevance of this plasma exposure and blood glucose information is unknown